- Home
- HUMA
HUMA
Humacyte Inc.
as 12-20-2024 4:00pm EST
Humacyte Inc is developing a disruptive biotechnology platform to deliver universally implantable bioengineered human tissues and organs designed to improve the lives of patients and transform the practice of medicine. It develops and manufactures acellular tissues to treat a wide range of diseases, injuries, and chronic conditions.
| Founded: | 2004 | Country: | United States |
| Employees: | N/A | City: | DURHAM |
| Market Cap: | 577.7M | IPO Year: | N/A |
| Target Price: | $13.14 | AVG Volume (30 days): | 6.3M |
| Analyst Decision: | Strong Buy | Number of Analysts: | 7 |
| Dividend Yield: | N/A | Dividend Payout Frequency: | N/A |
| EPS: | -1.36 | EPS Growth: | N/A |
| 52 Week Low/High: | $2.48 - $9.97 | Next Earning Date: | 11-08-2024 |
| Revenue: | N/A | Revenue Growth: | N/A |
| Revenue Growth (this year): | N/A | Revenue Growth (next year): | 6438.24% |
Latest Humacyte Inc. News
HUMA Breaking Stock News: Dive into HUMA Ticker-Specific Updates for Smart Investing
GlobeNewswire
3 days ago
Humacyte Announces FDA Approval of SYMVESS™ (acellular tissue engineered vessel-tyod) for the Treatment of Extremity Vascular Trauma
Simply Wall St.
4 days ago
Individual investors who have a significant stake must be disappointed along with institutions after Humacyte, Inc.'s (NASDAQ:HUMA) market cap dropped by US$60m
GlobeNewswire
20 days ago
Humacyte to Present at the Piper Sandler 36th Annual Healthcare Conference
GlobeNewswire
a month ago
Humacyte to Present Efficacy and Safety Results from V007 Phase 3 AV Access Clinical Trial at the 51st Annual Symposium on Vascular and Endovascular Issues, Techniques and Horizons (VEITH)
Simply Wall St.
a month ago
Insider Buyers At Humacyte Likely Disappointed With 17% Slide
GlobeNewswire
a month ago
Humacyte Clinical Results Highlighting Benefit of the ATEV™ in the Repair of Civilian and Military Arterial Injuries Published in JAMA Surgery
GlobeNewswire
a month ago
Humacyte Presents Preclinical Results of Small-Diameter ATEV™ for Coronary Artery Bypass Grafting at American Heart Association’s Scientific Sessions 2024
GlobeNewswire
a month ago
Humacyte Announces Pricing of $15.0 Million Registered Direct Offering
Compare HUMA vs Leading Stocks
Share on Social Networks:
Disclaimer
The information presented on this page, "HUMA Humacyte Inc. - Stocks Price | History | Analysis", including historical data, forecasts, news, insider information, and predictions, is provided for educational purposes only. It should not be considered as financial advice or a recommendation to buy or sell any securities. Decisions regarding investments should be made only after careful consideration and consultation with a qualified financial advisor. We do not endorse or guarantee the accuracy or reliability of the information provided, and we disclaim any liability for financial losses incurred as a result of decisions made based on the information presented.